Utah Medicaid and tirzepatide
We could not read Utah Medicaid's current criteria, so its coverage of Wegovy and Zepbound for weight loss is not confirmed. KFF listed it as covering them in January 2026, a dated secondary source, and reported that funding was limited to fiscal year 2026, which ended June 30, 2026, so a change may have taken effect.
In 2025 Utah Medicaid paid for 8,455 tirzepatide prescriptions (Mounjaro, Zepbound), 30% of its GLP-1 prescriptions and 37th of the 50 states and DC. It reimbursed $8.9 million before rebates, $1,054 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 8,377 | $8.8 million | $1,054 |
| Zepbound | 78 | $80,079 | $1,027 |
Tirzepatide in the states around Utah
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Utah | 17 | $69/moWellmedr | 8,455 | Medicaid Zepbound: Not confirmed (KFF) |
| Arizona | 17 | $69/moWellmedr | 6,126 | Medicaid Zepbound: Unclear |
| Colorado | 17 | $69/moWellmedr | 32,029 | Medicaid Zepbound: No |
| Idaho | 17 | $69/moWellmedr | 12,492 | Medicaid Zepbound: Not covered (KFF) |
| Nevada | 17 | $69/moWellmedr | 19,540 | Medicaid Zepbound: No |
| New Mexico | 17 | $69/moWellmedr | 18,921 | Medicaid Zepbound: No |
| Wyoming | 17 | $69/moWellmedr | 738 | Medicaid Zepbound: No |



